PaxVax Initiates Phase 3 Clinical Trial Challenge Studies for Single-Dose Oral Cholera Vaccine

New Vaccine Candidate, If Approved, Will Be the Only Cholera Vaccine Available in the US

Menlo Park, Calif., – September 6, 2013 – PaxVax Inc, which develops and commercializes innovative vaccines against infectious diseases in a socially responsible manner, today announced that it has commenced its Phase 3 clinical trial program for its single-dose oral cholera vaccine candidate, PXVX0200 (also known as CVD 103-HgR). Approximately 3,000 participants will be enrolled in this pivotal program, which is comprised of cholera challenge, safety, and immunogenicity studies.

Pages

Cholera

18.97
-72.29

Anthrax

40.71
-74.01

Typhoid

21.00
78.00

Hepatitis A

39.92
32.83

H5N1, Dengue

& HIV

-0.78
113.92

for protection wherever you are and wherever you go

PaxVax is a fully integrated specialty vaccine company committed to developing and commercializing innovative vaccines against infectious diseases.

PaxVax: Better Vaccines

37.44
-122.14
Subscribe to PaxVax - Socially Responsible Vaccines RSS